{
    "info": {
        "nct_id": "NCT02900976",
        "official_title": "A Pilot Study of Rituximab (RTX) and Third Party Latent Membrane Protein (LMP)-Specific Cytotoxic T-Lymphocytes (LMP-TC) in Pediatric Solid Organ Recipients (SOT) With EBV-Positive CD20-Positive Post-Transplant Lymphoproliferative Disease (PTLD)",
        "inclusion_criteria": "* Patient must have a history of solid organ transplantation\n* Patients must have biopsy-proven newly diagnosed, relapsed or refractory polymorphic or monomorphic PTLD using the World Health Organization (WHO) classification and that is:\n\n  * CD20 positive\n  * EBV positive by Epstein-Barr virus early ribonucleic acid (RNA) (EBER) in situ hybridization (preferred) and/or LMP immunoperoxidase staining\n* There must be evaluable disease at study entry either by imaging or by serial endoscopic biopsies.\n\n  * Note: a measurable node must have an LDi (longest diameter) greater than 1.5 cm; a measurable extranodal lesion should have an LDi greater than 1.0 cm; all tumor measurements must be recorded in millimeters (or decimal fractions of centimeters)\n* Patients must be considered medically refractory to decreased immunosuppression (50% or greater reduction) for at least 1 week or there must be documentation in the medical chart that decreased immunosuppression would be associated with an unacceptable risk of rejection\n* Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0 or 1\n\n  * Use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age\n* Patients must have a life expectancy of >= 8 weeks\n* Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study\n* Myelosuppressive chemotherapy: must not have received within 2 weeks of entry onto this study\n* COHORT A and B: Patient must not have received therapy with anti-CD20 monoclonal antibodies within 90 days of entry onto this study\n* COHORT C: Patient must have received rituximab at 375 mg/m^2 weekly for at least 3 doses within the last 90 days prior to study enrollment\n* Must not have received any prior radiation to any sites of measurable disease\n* Must not have received any prior stem cell transplant\n* Must not have received investigational therapy within 30 days of entry onto this study\n* Must not have received prior EBV or LMP-specific T cells within 90 days of entry onto this study\n* Must not have received alemtuzumab or other anti-T-cell antibody therapy within 28 days of entry onto this study\n* COHORT C: HLA typing is available and will be submitted at the time of enrollment.\nHealthy volunteers allowed\nMust have maximum age of 29 Years",
        "exclusion_criteria": "* Burkitt morphology\n* Central nervous system (CNS) involvement; CNS status must be confirmed by lumbar puncture\n\n  * Note: lumbar puncture can be performed at the time of diagnosis and does not need to be repeated unless there is a change in neurological status or it was performed more than 14 days prior to study entry\n* Bone marrow involvement (> 25%)\n\n  * Note: bone marrow aspiration/biopsy can be performed at the time of diagnosis and does not need to be repeated unless there is a change in peripheral blood counts or it was performed more than 14 days prior to study entry\n* Fulminant PTLD defined as: fever > 38 degrees Celsius (C), hypotension, and evidence of multi-organ involvement/failure including two or more of the following:\n\n  * Bone marrow (including pancytopenia without any detectable B-cell proliferation)\n  * Liver (coagulopathy, transaminitis and/or hyperbilirubinemia)\n  * Lungs (interstitial pneumonitis with or without pleural effusions)\n  * Gastrointestinal hemorrhage\n* Any documented donor-derived PTLD\n* Hepatitis B or C serologies consistent with past or current infections because of the risk of reactivation with rituximab\n* Severe and/or symptomatic refractory concurrent infection other than EBV\n* Pregnant females are ineligible since there is no available information regarding human fetal or teratogenic toxicities\n* Lactating females are not eligible unless they have agreed not to breastfeed their infants\n* Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained\n* Sexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of their study participation and for 12 months following completion of study therapy.\n* All patients and/or their parents or legal guardians must sign a written informed consent\n* All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Patients must be considered medically refractory to decreased immunosuppression (50% or greater reduction) for at least 1 week or there must be documentation in the medical chart that decreased immunosuppression would be associated with an unacceptable risk of rejection",
            "criterions": [
                {
                    "exact_snippets": "Patients must be considered medically refractory to decreased immunosuppression (50% or greater reduction) for at least 1 week",
                    "criterion": "refractoriness to decreased immunosuppression",
                    "requirements": [
                        {
                            "requirement_type": "refractoriness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "immunosuppression reduction",
                            "expected_value": {
                                "operator": ">=",
                                "value": 50,
                                "unit": "%"
                            }
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "week"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "documentation in the medical chart that decreased immunosuppression would be associated with an unacceptable risk of rejection",
                    "criterion": "risk of rejection with decreased immunosuppression",
                    "requirements": [
                        {
                            "requirement_type": "risk level",
                            "expected_value": "unacceptable"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* COHORT C: Patient must have received rituximab at 375 mg/m^2 weekly for at least 3 doses within the last 90 days prior to study enrollment",
            "criterions": [
                {
                    "exact_snippets": "Patient must have received rituximab at 375 mg/m^2 weekly for at least 3 doses within the last 90 days prior to study enrollment",
                    "criterion": "rituximab treatment",
                    "requirements": [
                        {
                            "requirement_type": "drug",
                            "expected_value": "rituximab"
                        },
                        {
                            "requirement_type": "dose",
                            "expected_value": {
                                "operator": "=",
                                "value": 375,
                                "unit": "mg/m^2"
                            }
                        },
                        {
                            "requirement_type": "frequency",
                            "expected_value": "weekly"
                        },
                        {
                            "requirement_type": "number of doses",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "doses"
                            }
                        },
                        {
                            "requirement_type": "time since last dose",
                            "expected_value": {
                                "operator": "<=",
                                "value": 90,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* CD20 positive",
            "criterions": [
                {
                    "exact_snippets": "CD20 positive",
                    "criterion": "CD20 expression",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have biopsy-proven newly diagnosed, relapsed or refractory polymorphic or monomorphic PTLD using the World Health Organization (WHO) classification and that is:",
            "criterions": [
                {
                    "exact_snippets": "biopsy-proven",
                    "criterion": "diagnosis confirmation by biopsy",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "biopsy-proven"
                        }
                    ]
                },
                {
                    "exact_snippets": "newly diagnosed, relapsed or refractory",
                    "criterion": "disease status",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": [
                                "newly diagnosed",
                                "relapsed",
                                "refractory"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "polymorphic or monomorphic PTLD",
                    "criterion": "PTLD subtype",
                    "requirements": [
                        {
                            "requirement_type": "subtype",
                            "expected_value": [
                                "polymorphic",
                                "monomorphic"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "using the World Health Organization (WHO) classification",
                    "criterion": "diagnostic classification system",
                    "requirements": [
                        {
                            "requirement_type": "classification system",
                            "expected_value": "World Health Organization (WHO)"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* EBV positive by Epstein-Barr virus early ribonucleic acid (RNA) (EBER) in situ hybridization (preferred) and/or LMP immunoperoxidase staining",
            "criterions": [
                {
                    "exact_snippets": "EBV positive by Epstein-Barr virus early ribonucleic acid (RNA) (EBER) in situ hybridization (preferred)",
                    "criterion": "Epstein-Barr virus (EBV) status by EBER in situ hybridization",
                    "requirements": [
                        {
                            "requirement_type": "positivity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "EBV positive by ... and/or LMP immunoperoxidase staining",
                    "criterion": "Epstein-Barr virus (EBV) status by LMP immunoperoxidase staining",
                    "requirements": [
                        {
                            "requirement_type": "positivity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* There must be evaluable disease at study entry either by imaging or by serial endoscopic biopsies.",
            "criterions": [
                {
                    "exact_snippets": "There must be evaluable disease at study entry",
                    "criterion": "evaluable disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at study entry"
                        }
                    ]
                },
                {
                    "exact_snippets": "either by imaging or by serial endoscopic biopsies",
                    "criterion": "evaluable disease assessment method",
                    "requirements": [
                        {
                            "requirement_type": "assessment_method",
                            "expected_value": [
                                "imaging",
                                "serial endoscopic biopsies"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Note: a measurable node must have an LDi (longest diameter) greater than 1.5 cm; a measurable extranodal lesion should have an LDi greater than 1.0 cm; all tumor measurements must be recorded in millimeters (or decimal fractions of centimeters)",
            "criterions": [
                {
                    "exact_snippets": "a measurable node must have an LDi (longest diameter) greater than 1.5 cm",
                    "criterion": "measurable node",
                    "requirements": [
                        {
                            "requirement_type": "longest diameter",
                            "expected_value": {
                                "operator": ">",
                                "value": 1.5,
                                "unit": "cm"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "a measurable extranodal lesion should have an LDi greater than 1.0 cm",
                    "criterion": "measurable extranodal lesion",
                    "requirements": [
                        {
                            "requirement_type": "longest diameter",
                            "expected_value": {
                                "operator": ">",
                                "value": 1.0,
                                "unit": "cm"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "all tumor measurements must be recorded in millimeters (or decimal fractions of centimeters)",
                    "criterion": "tumor measurements",
                    "requirements": [
                        {
                            "requirement_type": "measurement units",
                            "expected_value": [
                                "millimeters",
                                "decimal fractions of centimeters"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0 or 1",
            "criterions": [
                {
                    "exact_snippets": "performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0 or 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": ""
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": ""
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have a life expectancy of >= 8 weeks",
            "criterions": [
                {
                    "exact_snippets": "life expectancy of >= 8 weeks",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 8,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient must have a history of solid organ transplantation",
            "criterions": [
                {
                    "exact_snippets": "history of solid organ transplantation",
                    "criterion": "solid organ transplantation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Use Karnofsky for patients > 16 years of age and Lansky for patients =< 16 years of age",
            "criterions": [
                {
                    "exact_snippets": "Karnofsky for patients > 16 years of age",
                    "criterion": "performance status scale",
                    "requirements": [
                        {
                            "requirement_type": "scale used",
                            "expected_value": "Karnofsky"
                        },
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">",
                                "value": 16,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Lansky for patients =< 16 years of age",
                    "criterion": "performance status scale",
                    "requirements": [
                        {
                            "requirement_type": "scale used",
                            "expected_value": "Lansky"
                        },
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": "<=",
                                "value": 16,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study",
            "criterions": [
                {
                    "exact_snippets": "fully recovered from the acute toxic effects of all prior chemotherapy",
                    "criterion": "recovery from acute toxic effects of prior chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "recovery_status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "fully recovered from the acute toxic effects of all prior ... immunotherapy",
                    "criterion": "recovery from acute toxic effects of prior immunotherapy",
                    "requirements": [
                        {
                            "requirement_type": "recovery_status",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "fully recovered from the acute toxic effects of all prior ... radiotherapy",
                    "criterion": "recovery from acute toxic effects of prior radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "recovery_status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Myelosuppressive chemotherapy: must not have received within 2 weeks of entry onto this study",
            "criterions": [
                {
                    "exact_snippets": "Myelosuppressive chemotherapy: must not have received within 2 weeks of entry onto this study",
                    "criterion": "myelosuppressive chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last administration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* COHORT A and B: Patient must not have received therapy with anti-CD20 monoclonal antibodies within 90 days of entry onto this study",
            "criterions": [
                {
                    "exact_snippets": "Patient must not have received therapy with anti-CD20 monoclonal antibodies within 90 days of entry onto this study",
                    "criterion": "anti-CD20 monoclonal antibody therapy",
                    "requirements": [
                        {
                            "requirement_type": "exposure within last 90 days",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Must not have received any prior radiation to any sites of measurable disease",
            "criterions": [
                {
                    "exact_snippets": "Must not have received any prior radiation to any sites of measurable disease",
                    "criterion": "prior radiation to sites of measurable disease",
                    "requirements": [
                        {
                            "requirement_type": "history of prior radiation",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Must not have received any prior stem cell transplant",
            "criterions": [
                {
                    "exact_snippets": "Must not have received any prior stem cell transplant",
                    "criterion": "prior stem cell transplant",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Must not have received investigational therapy within 30 days of entry onto this study",
            "criterions": [
                {
                    "exact_snippets": "Must not have received investigational therapy within 30 days of entry onto this study",
                    "criterion": "receipt of investigational therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last receipt",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Must not have received alemtuzumab or other anti-T-cell antibody therapy within 28 days of entry onto this study",
            "criterions": [
                {
                    "exact_snippets": "Must not have received alemtuzumab or other anti-T-cell antibody therapy within 28 days of entry onto this study",
                    "criterion": "alemtuzumab or other anti-T-cell antibody therapy",
                    "requirements": [
                        {
                            "requirement_type": "exposure within time window",
                            "expected_value": {
                                "operator": "<",
                                "value": 28,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Must not have received prior EBV or LMP-specific T cells within 90 days of entry onto this study",
            "criterions": [
                {
                    "exact_snippets": "Must not have received prior EBV or LMP-specific T cells within 90 days of entry onto this study",
                    "criterion": "prior EBV or LMP-specific T cell therapy",
                    "requirements": [
                        {
                            "requirement_type": "receipt within 90 days",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have maximum age of 29 Years",
            "criterions": [
                {
                    "exact_snippets": "maximum age of 29 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "maximum",
                            "expected_value": {
                                "operator": "<=",
                                "value": 29,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* COHORT C: HLA typing is available and will be submitted at the time of enrollment.",
            "criterions": [
                {
                    "exact_snippets": "HLA typing is available",
                    "criterion": "HLA typing",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "will be submitted at the time of enrollment",
                    "criterion": "HLA typing",
                    "requirements": [
                        {
                            "requirement_type": "submission timing",
                            "expected_value": "at the time of enrollment"
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Gastrointestinal hemorrhage",
            "criterions": [
                {
                    "exact_snippets": "Gastrointestinal hemorrhage",
                    "criterion": "gastrointestinal hemorrhage",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Bone marrow involvement (> 25%)",
            "criterions": [
                {
                    "exact_snippets": "Bone marrow involvement (> 25%)",
                    "criterion": "bone marrow involvement",
                    "requirements": [
                        {
                            "requirement_type": "percentage",
                            "expected_value": {
                                "operator": ">",
                                "value": 25,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Liver (coagulopathy, transaminitis and/or hyperbilirubinemia)",
            "criterions": [
                {
                    "exact_snippets": "Liver (coagulopathy",
                    "criterion": "liver coagulopathy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Liver (... transaminitis",
                    "criterion": "liver transaminitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Liver (... hyperbilirubinemia",
                    "criterion": "liver hyperbilirubinemia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Burkitt morphology",
            "criterions": [
                {
                    "exact_snippets": "Burkitt morphology",
                    "criterion": "Burkitt morphology",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* All patients and/or their parents or legal guardians must sign a written informed consent",
            "criterions": [
                {
                    "exact_snippets": "All patients and/or their parents or legal guardians must sign a written informed consent",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "signed",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained",
            "criterions": [
                {
                    "exact_snippets": "Female patients of childbearing potential",
                    "criterion": "female patients of childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "not eligible unless a negative pregnancy test result has been obtained",
                    "criterion": "pregnancy test result",
                    "requirements": [
                        {
                            "requirement_type": "test result",
                            "expected_value": "negative"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any documented donor-derived PTLD",
            "criterions": [
                {
                    "exact_snippets": "Any documented donor-derived PTLD",
                    "criterion": "donor-derived PTLD",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "documentation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Bone marrow (including pancytopenia without any detectable B-cell proliferation)",
            "criterions": [
                {
                    "exact_snippets": "Bone marrow (including pancytopenia without any detectable B-cell proliferation)",
                    "criterion": "bone marrow",
                    "requirements": [
                        {
                            "requirement_type": "condition",
                            "expected_value": "pancytopenia without any detectable B-cell proliferation"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Severe and/or symptomatic refractory concurrent infection other than EBV",
            "criterions": [
                {
                    "exact_snippets": "Severe and/or symptomatic refractory concurrent infection other than EBV",
                    "criterion": "concurrent infection (other than EBV)",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "severe"
                        },
                        {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "refractory",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Fulminant PTLD defined as: fever > 38 degrees Celsius (C), hypotension, and evidence of multi-organ involvement/failure including two or more of the following:",
            "criterions": [
                {
                    "exact_snippets": "fever > 38 degrees Celsius (C)",
                    "criterion": "fever",
                    "requirements": [
                        {
                            "requirement_type": "temperature",
                            "expected_value": {
                                "operator": ">",
                                "value": 38,
                                "unit": "degrees Celsius"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "hypotension",
                    "criterion": "hypotension",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "evidence of multi-organ involvement/failure including two or more of the following",
                    "criterion": "multi-organ involvement/failure",
                    "requirements": [
                        {
                            "requirement_type": "number of organs involved/failed",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "organs"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pregnant females are ineligible since there is no available information regarding human fetal or teratogenic toxicities",
            "criterions": [
                {
                    "exact_snippets": "Pregnant females are ineligible",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnancy",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Note: lumbar puncture can be performed at the time of diagnosis and does not need to be repeated unless there is a change in neurological status or it was performed more than 14 days prior to study entry",
            "criterions": [
                {
                    "exact_snippets": "lumbar puncture can be performed at the time of diagnosis and does not need to be repeated unless ... it was performed more than 14 days prior to study entry",
                    "criterion": "lumbar puncture",
                    "requirements": [
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": "<=",
                                "value": 14,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "lumbar puncture can be performed at the time of diagnosis and does not need to be repeated unless there is a change in neurological status",
                    "criterion": "neurological status",
                    "requirements": [
                        {
                            "requirement_type": "change",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Central nervous system (CNS) involvement; CNS status must be confirmed by lumbar puncture",
            "criterions": [
                {
                    "exact_snippets": "Central nervous system (CNS) involvement",
                    "criterion": "central nervous system (CNS) involvement",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "CNS status must be confirmed by lumbar puncture",
                    "criterion": "CNS status confirmation by lumbar puncture",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "lumbar puncture"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Lactating females are not eligible unless they have agreed not to breastfeed their infants",
            "criterions": [
                {
                    "exact_snippets": "Lactating females are not eligible",
                    "criterion": "lactating status",
                    "requirements": [
                        {
                            "requirement_type": "lactating",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "unless they have agreed not to breastfeed their infants",
                    "criterion": "agreement to not breastfeed",
                    "requirements": [
                        {
                            "requirement_type": "agreement to not breastfeed",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Lungs (interstitial pneumonitis with or without pleural effusions)",
            "criterions": [
                {
                    "exact_snippets": "Lungs (interstitial pneumonitis",
                    "criterion": "interstitial pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "pleural effusions",
                    "criterion": "pleural effusions",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Note: bone marrow aspiration/biopsy can be performed at the time of diagnosis and does not need to be repeated unless there is a change in peripheral blood counts or it was performed more than 14 days prior to study entry",
            "criterions": [
                {
                    "exact_snippets": "bone marrow aspiration/biopsy can be performed at the time of diagnosis and does not need to be repeated unless there is a change in peripheral blood counts",
                    "criterion": "peripheral blood counts",
                    "requirements": [
                        {
                            "requirement_type": "change",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* All institutional, Food and Drug Administration (FDA), and National Cancer Institute (NCI) requirements for human studies must be met",
            "criterions": [
                {
                    "exact_snippets": "All institutional ... requirements for human studies must be met",
                    "criterion": "institutional requirements for human studies",
                    "requirements": [
                        {
                            "requirement_type": "compliance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Food and Drug Administration (FDA) ... requirements for human studies must be met",
                    "criterion": "FDA requirements for human studies",
                    "requirements": [
                        {
                            "requirement_type": "compliance",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "National Cancer Institute (NCI) requirements for human studies must be met",
                    "criterion": "NCI requirements for human studies",
                    "requirements": [
                        {
                            "requirement_type": "compliance",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Sexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of their study participation and for 12 months following completion of study therapy.",
            "criterions": [
                {
                    "exact_snippets": "Sexually active patients of reproductive potential are not eligible unless they have agreed to use an effective contraceptive method for the duration of their study participation and for 12 months following completion of study therapy.",
                    "criterion": "use of effective contraceptive method",
                    "requirements": [
                        {
                            "requirement_type": "agreement to use",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration of use",
                            "expected_value": [
                                "for the duration of their study participation",
                                "for 12 months following completion of study therapy"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hepatitis B or C serologies consistent with past or current infections because of the risk of reactivation with rituximab",
            "criterions": [
                {
                    "exact_snippets": "Hepatitis B or C serologies consistent with past or current infections",
                    "criterion": "Hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "serology status",
                            "expected_value": "consistent with past or current infection"
                        }
                    ]
                },
                {
                    "exact_snippets": "Hepatitis B or C serologies consistent with past or current infections",
                    "criterion": "Hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "serology status",
                            "expected_value": "consistent with past or current infection"
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}